Patients who stop taking popular weight-loss medications like Ozempic, Wegovy, or Mounjaro frequently regain a significant portion of lost weight, prompting a growing number of individuals to seek bariatric surgery as a permanent alternative, according to Op. Dr. Volkan Arayici.
Why Patients Abandon GLP-1 Medications for Surgery
The rise of GLP-1 receptor agonists has transformed obesity care, yet it has also created a distinct patient population. According to Op. Dr. Volkan Arayici, a specialist in general surgery with a focus on obesity and metabolic surgery based in Izmir, many patients achieve substantial weight loss on medications like tirzepatid or semaglutide only to stop treatment due to prohibitive out-of-pocket costs or persistent side effects. Monthly expenses for these drugs reach approximately 350 euros for Ozempic or Wegovy and roughly 420 euros for Mounjaro, with statutory health insurance in Germany not covering the treatments for obesity.
“The majority of patients coming to us from Germany today have previously used Ozempic, Wegovy, or Mounjaro,” Arayici states. Beyond financial strain, patients frequently report side effects such as ongoing nausea, vomiting, and notable muscle mass loss caused by inadequate protein intake while on the appetite-suppressing drugs. When these factors force patients to quit the therapy, the underlying metabolic drivers of obesity reassert themselves, leading to weight regain.
Evaluating Bariatric Surgery After GLP-1 Therapy
Not every patient dissatisfied with injectable treatments requires an operation. Arayici outlines four specific clinical criteria that make bariatric surgery an appropriate next step:
- Achieving less than 10 percent total body weight loss after 12 months of consistent medical therapy.
- Maintaining a body mass index (BMI) above 40 despite medication use, or above 35 accompanied by obesity-related comorbidities like type 2 diabetes or sleep apnea.
- Encountering side effects or financial barriers that render long-term medical therapy impossible.
- Discontinuing the injections and subsequently regaining the lost weight.
For individuals with a BMI under 35 and no weight-related health conditions, continued medical management remains the appropriate path. Surgical options in Arayici’s practice, such as a sleeve gastrectomy starting at 3,500 euros or gastric bypass starting at 4,000 euros, covering pre-operative diagnostics, a four-night hospital stay, local transfers, and 12 months of follow-up care via WhatsApp and video calls.
Surgical Preparation and the Sequencing of Treatments
A common misconception involves the timeline for stopping GLP-1 medications prior to an operation. Arayici notes that patients do not need to discontinue injections weeks in advance or follow a restrictive liver-shrinking diet. Because GLP-1 receptor agonists slow gastric emptying, the clinical recommendation is to take the final dose roughly one week before surgery to ensure the stomach is completely empty for safe anesthesia.
Conversely, the treatment sequence reverses for patients who experience weight regain years after undergoing a sleeve gastrectomy or gastric bypass. In those cases, clinicians administer a GLP-1 therapy and perform an upper endoscopy before considering any secondary surgical intervention. “The injection does not replace surgery, and surgery does not replace the injection,” Arayici explains. “Both have their place—in the correct order.”
Worth a look